Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › arteriovenous fistula

Arteriovenous fistula

Part of Arteriovenous Malformations

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for arteriovenous fistula

7 trials tracked for arteriovenous fistula: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 144 citations.

7Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 2 Phase 2 1 Other / NA 3
  1. Phase 3 Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae Completed · 144 cited
  2. Phase 4 Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients Completed
  3. Phase 3 Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Completed
  4. Phase 2 An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access Completed
  5. N/A IN.PACT™ AV Access IDE Study Completed
  6. N/A Prospective Feasibility Study Evaluating EchoMark LP Placement and EchoSure Measurements for Subjects Requiring Arteriovenous Fistulae Completed
Show 1 more trials
  1. N/A Arteriovenous Fistula Cannulation Practices and Dialysis Adequacy Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Arteriovenous fistula: what the trials found

Clinical evidence for arteriovenous fistula management includes the use of topical Tranexamic Acid 5% with bacitracin 1.

The Lutonix DCB demonstrated a 71.4% Target Lesion Primary Patency (TLPP) at 6 months post-procedure, which was significantly higher than the comparison group (63%, p=0.0562). However, TLPP rates for this intervention showed a decline over time, reaching 36% at 24 months 2. Additionally, the Lutonix DCB was associated with a significantly higher number of participants achieving freedom from any serious adverse events involving the AV access circuit at 30 days post-procedure (138 vs. 130, p=0.002) 2.

Sirolimus was evaluated for fistula suitability for dialysis at 6 months (FSD6), showing no statistically significant difference between groups (74 vs. 76, p=0.2942) 3.

Recent results — preliminary, needs further review

  • SRM003 showed maturation rates of 96.6% and 85.7% at week 12 (p=0.1197) and 96.6% and 88.6% at week 26 (p=0.1962), with a mean time to maturation of 9 vs. 10 weeks (p=0.090) 4.
  • The EchoMark / EchoSure system achieved a technical success rate of 270 for determining blood flow, diameter, and depth measurements from baseline to 4 months 5.
  • IN.PACT AV DCB showed a significantly higher Target Lesion Primary Patency Rate through 6 months (125 vs. 88, p=<0.001) and a significant difference in the primary safety endpoint for serious adverse events (7 vs. 7, p=0.002) 7.

For the clinician treating this condition

  • Lutonix DCB provides superior protection against serious adverse events involving the AV access circuit at 30 days compared to the alternative 2.
  • While Lutonix DCB shows high initial patency, there is a notable decline in target lesion primary patency over a 24-month period 2.
  • Sirolimus does not show a statistically significant difference in fistula suitability for dialysis at 6 months compared to the control 3.

AI synthesis of 6 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Physical therapy and respiratory exercises reduce pain scores in patients with arteriovenous fistulas
Anesthesiology & Pain Medicine Sys. Review
Physical therapy and respiratory exercises reduce pain scores in patients with arteriovenous fistulas Physical Therapy May Ease Pain From Dialysis Fistulas
This meta-analysis of 865 patients found that physical therapy is associated with improved pain symptoms in patients with arteriovenous fist…
A review of 865 patients suggests physical therapy, especially breathing exercises, may help ease pain from arteriovenous fistulas.
Oct 5, 2026
Self-management interventions for arteriovenous fistulas vary in duration, frequency, and theoretical framework
Emergency Medicine Sys. Review
Self-management interventions for arteriovenous fistulas vary in duration, frequency, and theoretical framework Self-Management Programs May Help Patients with Arteriovenous Fistulas
This scoping review of 15 studies examines self-management interventions for patients with arteriovenous fistulas undergoing hemodialysis. T…
New research looks at how self-management programs, including mobile apps and peer support, can help patients manage arteriovenous fistulas.
Frontiers Sep 17, 2026
Scoring paclitaxel-coated balloon angioplasty improves 6-month target lesion primary patency by 21.2 percentage points
Nephrology RCT
Scoring paclitaxel-coated balloon angioplasty improves 6-month target lesion primary patency by 21.2 percentage points Paclitaxel coated balloons improve blood flow for dialysis patients
This randomized controlled trial of 219 adults with malfunctioning arteriovenous fistulas or grafts found that scoring paclitaxel-coated bal…
A new balloon technique using a paclitaxel coating helps keep dialysis access sites open longer compared to standard treatments.
Aug 3, 2026
Systematic review confirms clip anastomosis improves one and two year primary patency rates for arteriovenous fistula creation compared to suture methods
Nephrology Meta-analysis
Systematic review confirms clip anastomosis improves one and two year primary patency rates for arteriovenous fistula creation compared to suture methods Vascular Clips Outperform Sutures for Dialysis Access Longevity
A comprehensive meta-analysis of 2,964 patients indicates that clip anastomosis significantly enhances one-year and two-year primary patency…
• Clips keep dialysis access open longer than sutures • Helps kidney patients needing reliable treatment lifelines • Not ready for all clini…
May 6, 2026
Meta-analysis shows systemic heparinization reduces early patency loss in adult AVF or graft placement
Nephrology Meta-analysis
Meta-analysis shows systemic heparinization reduces early patency loss in adult AVF or graft placement Systemic heparin lowers early clot risk but raises bleeding danger for arm access patients
This meta-analysis evaluated systemic heparinization versus standard care in adults undergoing arm arteriovenous fistula or graft placement.
A large analysis shows systemic heparin cuts early clot risk for arm access but increases bleeding complications, requiring careful balance.
May 1, 2026

Questions about arteriovenous fistula

Does paclitaxel-coated balloon angioplasty improve the 6-month patency of an arteriovenous fistula?

Yes, a 2026 randomized trial found that a scoring paclitaxel-coated balloon improved 6-month target lesion patency of failing arteriovenous fistulas compared with a plain balloon (78.9% vs 57.3%) [9].

Full answer →
What types of self-management programs are available for patients with an arteriovenous fistula?

Self-management programs for arteriovenous fistulas (AVFs) can include physical therapy, respiratory exercises, and programs based on various behavioral and nursing theories.

Full answer →
Does paclitaxel-coated balloon angioplasty improve the patency of a malfunctioning arteriovenous fistula?

Yes. A 2026 multicenter randomized trial found that a scoring paclitaxel-coated balloon improved 6-month target lesion primary patency (78.9% vs 57.3%) compared with plain balloon angioplasty in failing arteriovenous access [9].

Full answer →